ICICI Securities has started coverage on Emcure Pharmaceuticals with a 'Buy' rating and a price target of Rs 2,305. The brokerage highlights potential growth from chronic therapies and international expansion, while the stock also trades ex-dividend today.
ICICI Securities initiated coverage on Emcure Pharmaceuticals on Friday, assigning a 'Buy' rating with a price target of Rs 2,305 per share. This target is based on the brokerage's projection for the company’s earnings per share (EPS) in fiscal year 2028, to which they applied a 30x valuation multiple. The announcement comes on the same day the company held an institutional investor meeting in Pune and traded ex-dividend, meaning investors buying the stock today are not eligible for the final dividend of Rs 3.60 per share.
The brokerage's optimistic view centers on the company’s ability to grow through its diversified business model. Emcure holds a strong market position in India, particularly within chronic therapeutic areas, and maintains a leading presence in women's healthcare. This, combined with a significant injectables franchise, provides a stable revenue foundation. Beyond its current portfolio, the company is focusing on international growth in regions such as Canada and Europe, largely driven by an acquisition-led strategy.
Another key driver identified by the analysts is Emcure's approach to product innovation. Rather than relying solely on expensive, internal research and development, the company is using in-licensing partnerships. This strategy aims to bring niche products—such as those for GLP-1, MASH, and ophthalmology—to the market more efficiently. This approach is intended to help the company expand its product pipeline while managing capital spending.
While the growth outlook appears positive, investors should also account for operational and market-related risks. The company is currently working on integrating recent acquisitions, including Zuventus, which carries the risk of restructuring costs and potential disruption. Additionally, the firm’s international operations are exposed to foreign exchange fluctuations, which can impact reported earnings. Other factors that could influence performance include volatility in the prices of raw materials and solvents, and the competitive nature of the complex generics market, which involves potential patent challenges.
Looking ahead, the primary monitorables for shareholders will be the successful execution of these integration plans, the management of profit margins amidst rising operational costs, and the company's ability to maintain its market share in the face of increasing competition in high-growth therapeutic areas.